Adjusting Surface Oxidized Layer of CoTe on PCN via In Situ N-Doping Strategy to Promote Charge Separation of Z-Scheme Heterojunction for Propelling Photocatalytic CO Reduction.

It has been a challenging issue to profoundly actuate the transfer and separation of photoinduced charge carriers by controlling the interface structure inside the heterojunction, owing to the molecular/subnanometric level interface region. Herein, a unique one-dimensional/two-dimensional (1D/2D) CoTe/PCN Z-scheme heterojunction is fabricated through the self-assembly of CoTe nanorods on the surface of polymeric carbon nitride (PCN) nanosheets. Significantly, in situ N-doping in the molecular/subnanometric surface oxidized layer of CoTe nanorods is achieved, effectively adjusting its chemical structure and element chemical states.

3D/2D Heterojunction Fabricated from RuS Nanospheres Encapsulated in Polymeric Carbon Nitride Nanosheets for Selective Photocatalytic CO Reduction to CO.

Micro/nanostructure control of heterostructures is still a challenge for achieving high efficiency and selectivity of photocatalytic CO conversion. In this work, a new three-dimensiona/two-dimensional (3D/2D) heterostructure is fabricated by encapsulating RuS nanospheres in the interlayer of mesoporous polymeric carbon nitride (PCN) nanosheets based on an in situ growth and polymerization strategy. The unique microstructure of the obtained 3D/2D RuS/PCN heterojunction can effectively improve the transfer and separation efficiency of photogenerated charge carriers, reduce the mass transfer resistance of CO toward active sites, and provide a confined reaction space, thus propelling the photocatalytic CO reduction to CO with high selectivity.

A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mainly induces apoptosis through the extrinsic death receptor-induced pathway by ligation with death receptor 4 (DR4) and death receptor 5 (DR5). On the basis of the antitumor activity to cancer cells and no cytotoxity to normal cells of TRAIL and the target of the epidermal growth factor receptor (EGFR) ligand peptide, the study constructed a new bispecific fusion protein and a new bifunctional enediyne-energized fusion protein and investigated their antitumor efficacy. Bispecific fusion protein Ec-LDP-TRAIL showed potent binding activity to cancer cell lines with a high expression of EGFR or DR4/DR5 such as A431 and H460 cells, whereas poor binding activity to NIH/3T3 cells with low expressing EGFR and DR4/DR5.